支气管扩张：市场展望、流行病学、竞争格局和市场预测报告，2025-2035年

市场概览

• 预计德国支气管扩张症市场将经历温和至稳定的成长，这得益于诊断技术的改进和新治疗方法的出现，市场规模将从 2025 年的 1.08 亿美元增长到 2035 年的 1.67 亿美元。
• 市场扩张受以下因素支撑：
• 扩大吸入式抗生素和慢性病管理疗法的使用
• 提高对非化脓性痰（NCFB）的认识与诊断
• 虽然患者数量的成长较为温和（年复合成长率为 0.7%），但市场规模的成长是由慢性病治疗和復发性病情加重的管理所推动的。
• 未来的成长取决于开发针对潜在发炎和感染疾病的标靶治疗，从而改善疾病控制并减少病情加重的频率。

支气管扩张概述

支气管扩张是一种慢性进行性呼吸系统疾病，其特征是支气管不可逆性扩张，由持续感染或发炎损害气道结构所致。此疾病大致分为囊肿纤维化（CF）相关性支气管扩张和非囊肿纤维化支气管扩张（NCFB），后者占大多数病例，其病因多种多样，包括既往感染疾病（如结核病和肺炎）、免疫力缺乏、自体免疫疾病以及黏液纤毛清除功能障碍。其潜在的病理生理机制是由粘液清除功能障碍、慢性细菌定植（最常见的是铜绿假单胞菌和流感嗜血桿菌）以及持续性嗜中性白血球炎症构成的恶性循环所驱动的。这种恶性循环导致进行性性肺损伤、肺功能下降、復发性急性恶化风险增加。

临床上，患者表现为慢性咳嗽咳痰、频繁加重、呼吸困难和疲倦，导致生活品质显着下降。儘管人们对该疾病的认识不断提高，疾病负担日益加重，但治疗选择仍然有限，主要包括症状治疗，例如气道清理技术、抗生素和支持疗法。治疗前景正在改变，目前的研究重点是吸入性抗生素、祛痰药和抗发炎疗法，旨在打破感染和发炎的恶性循环，并改善长期预后。

主要亮点

• 在德国，预计确诊病例数将从 2025 年的 44,900 例增加到 2035 年的 48,100 例，呈稳定成长趋势（年复合成长率为 0.7%）。
• 这种疾病的特征是反覆加重和慢性感染，导致肺功能进行性下降，对医疗保健造成沉重负担。
• 疾病修正治疗的选择有限，凸显了巨大的未满足需求，导致人们更加关注吸入式抗生素和抗发炎药物。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• GlaxoSmithKline
• AstraZeneca
• CSL Behring
• S-INFINITY Pharmaceuticals Co., Ltd
• Shanghai Huilun Pharmaceutical Co., Ltd.
• Boehringer Ingelheim
• Haisco Pharmaceutical Group Co., Ltd.
• Thirty Respiratory Limited
• Genentech, Inc.
• Verona Pharma plc
• Sanofi
• Chiesi Farmaceutici SpA
• Armata Pharmaceuticals, Inc.
• Renovion, Inc.
• Insmed Incorporated
• Reistone Biopharma Company Limited

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
• 重点
• 诊断和治疗过程/演算法
• 主要治疗方法概述及KOL洞察
• 新兴治疗方法
• 重点
• 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
• 值得关注的早期研发管线

第六章：未满足的需求与TPP分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Bronchiectasis Market Outlook

Thelansis's "Bronchiectasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bronchiectasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Bronchiectasis Overview

Bronchiectasis is a chronic, progressive respiratory disorder characterized by irreversible dilation of the bronchi, resulting from persistent infection and inflammation that damage airway structure. The disease is broadly classified into cystic fibrosis (CF)-related and non-cystic fibrosis bronchiectasis (NCFB), with the latter accounting for the majority of cases and arising from diverse etiologies including prior infections (e.g., tuberculosis, pneumonia), immunodeficiency, autoimmune diseases, and impaired mucociliary clearance. The underlying pathophysiology is driven by a vicious cycle of impaired mucus clearance, chronic bacterial colonization-most commonly Pseudomonas aeruginosa and Haemophilus influenzae-and sustained neutrophilic inflammation. This cycle leads to progressive lung damage, declining pulmonary function, and increased susceptibility to recurrent exacerbations.

Clinically, patients present with chronic productive cough, frequent exacerbations, dyspnea, and fatigue, resulting in significant impairment in quality of life. Despite increasing disease recognition and burden, therapeutic options remain limited and largely symptomatic, including airway clearance techniques, antibiotics, and supportive care. The treatment landscape is evolving, with ongoing research focused on inhaled antibiotics, mucoactive agents, and anti-inflammatory therapies aimed at breaking the cycle of infection and inflammation and improving long-term outcomes.

Key Highlights

• In Germany, diagnosed prevalent cases are projected to increase from 44.9K in 2025 to 48.1K by 2035, reflecting steady growth (0.7% CAGR).
• The disease is characterized by recurrent exacerbations and chronic infection, contributing to progressive lung function decline and high healthcare burden.
• Limited availability of disease-modifying therapies highlights a significant unmet need, with increasing focus on inhaled antibiotics and anti-inflammatory agents.

Market Overview

• The Germany bronchiectasis market is projected to grow from $108M in 2025 to $167M by 2035, reflecting moderate-to-strong growth driven by improved diagnosis and emerging therapies.
• Market expansion is supported by:
• Increasing adoption of inhaled antibiotics and chronic management therapies
• Rising awareness and diagnosis of NCFB
• Despite moderate patient growth (0.7% CAGR), market value is driven by chronic treatment use and management of recurrent exacerbations.
• Future growth will depend on the development of targeted therapies that address underlying inflammation and infection, improving disease control and reducing exacerbation frequency.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• GlaxoSmithKline
• AstraZeneca
• CSL Behring
• S-INFINITY Pharmaceuticals Co., Ltd
• Shanghai Huilun Pharmaceutical Co., Ltd.
• Boehringer Ingelheim
• Haisco Pharmaceutical Group Co., Ltd.
• Thirty Respiratory Limited
• Genentech, Inc.
• Verona Pharma plc
• Sanofi
• Chiesi Farmaceutici S.p.A.
• Armata Pharmaceuticals, Inc.
• Renovion, Inc.
• Insmed Incorporated
• Reistone Biopharma Company Limited

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)